10x Genomics Profit Margin

10x Genomics (TXG) currently reports a profit margin of -10.84% as of September 2026. That compares with -11.89% in the prior-year period — up 8.8% year over year. That is below the Healthcare sector average of 19.13%. Use the charts on this page to explore 10x Genomics's profit margin history and peer comparisons.

10x Genomics's profit margin increased from -11.89% to -10.84% — a 8.8% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

10x Genomics's profit margin of -10.84% is lower than the Healthcare sector average of 19.13%. That is roughly 156.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but 10x Genomics's current -10.84% should be judged against Healthcare norms (sector average: 19.13%) and against TXG's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -10.84%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for 10x Genomics, and consider following TXG for alerts when major investors trade the stock.